GigaGen develops novel antibody therapies for patients with diseases that result from immune system dysregulation including cancer and immune deficiencies. Our proprietary approach delivers unprecedented insights into immune regulatory pathways and what causes them to fail, enabling a pipeline of first-in-class mono- and polyclonal antibody therapies.
